

Hepatitis B Virus Infection – High Endemic Geographic Areas

Children younger than seven years of age whose families have immigrated to Canada from areas where there is a high prevalence (8% or higher) of hepatitis B are at increased risk of hepatitis B infections even if neither parent is a chronic carrier. These children are likely to be exposed to hepatitis B carriers through their extended families or when visiting friends and relatives in their country of origin and should be offered hepatitis B vaccine. Immunization can start with the routine vaccination schedule at two months of age, with the next doses to complete the series given at four and 12 months of age. Hepatitis B vaccine series can be started at any age (two months up to seven years of age) for children identified who meet these eligibility criteria.

Countries considered highly endemic (8% or higher HBsAg prevalence) for hepatitis B infection are listed by geographical areas below:

Africa (all countries except Algeria, Egypt, Libya, Morocco and Tunisia)

Angola	Gabon	Rwanda
Benin	Gambia	Saint Helena
Botswana	Ghana	SaoTome and Principe
Burkina Faso	Guinea	Senegal
Burundi	Guinea-Bissau	Seychelles
Cameroon	Kenya	Sierra Leone
Cape Verde Islands	Lesotho	Somalia
Central African Republic	Liberia	South Africa
Chad	Madagascar	Sudan
Comoros	Malawi	Swaziland
Congo	Mali	Togo
Côte d'Ivoire	Mauritania	Uganda
Democratic Republic of the Congo	Mauritius	United Republic of Tanzania
Djibouti	Mozambique	Western Sahara
Equatorial Guinea	Namibia	Zambia
Eritrea	Niger	Zimbabwe
Ethiopia	Nigeria	
	Reunion Island	

Central and Eastern Europe (including the independent states of the former Soviet Union) and the Middle East

Albania	Georgia	Saudi Arabia
Armenia	Jordan	Tajikstan
Azerbaijan	Kazakhstan	Turkmenistan
Bulgaria	Kyrgyzstan	Uzbekistan
Denmark – Greenland (indigenous populations)	Malta	
	Republic of Moldova	

Central and South America (interior Amazon basin and parts of the Caribbean)

Bolivia (Amazon Basin)	Dominican Republic	Peru
Brazil (Amazon Basin)	Haiti	Venezuela (Amazon Basin)
Columbia (Amazon Basin)		

North America

High hepatitis B endemicity occurs in the Alaska Native populations and indigenous populations in Northern Canada.

Southeast Asia and the South and Western Pacific Islands


America Samoa		Palau
Cambodia		Papua New Guinea
China (includes Hong Kong, Macao and Taiwan)		Philippines
Cook Islands		Samoa
Easter Island		Solomon Islands
Federated States of Micronesia		Taiwan
Fiji	Source:	Thailand
French Polynesia	Korea (North and South)	Timor-Leste
Guam	Lao People's Democratic Republic	Tokelau
Hong Kong	Marshall Islands	Tonga
Indonesia	Macao	Trust Territories of Pacific Islands
Kiribati	Mongolia	Tuvalu
	Myanmar (Burma)	Vanuatu Vietnam
	Nauru	Wallis and Futuna Islands
	New Caledonia and Dependencies	
	Niue	

Alberta Health, Public Health and Compliance Division, Alberta Immunization Policy (2017, August).
Hepatitis B Virus Infection – High Endemic Geographic Areas

Appendix B


Hepatitis B Vaccine Recommendations Algorithm for Health Care Workers Not at High-Risk of Past Infection

*This algorithm is intended to be used in conjunction with the Standard for Immunization of Health Care Workers, Standard for Immunization of Post-Secondary Health Care Students and the Hepatitis B Vaccine Biological Page.



Hepatitis B Vaccine Recommendations Algorithm for Health Care Workers At High-Risk of Past Infection

*This algorithm is intended to be used in conjunction with the Standard for Immunization of Health Care Workers, Standard for Immunization of Post-Secondary Health Care Students and the Hepatitis B Vaccine Biological Page.



Notes:

- These recommendations apply to **pre-exposure** immunization only. Post-exposure recommendations fall under the notifiable disease management guidelines and blood/body fluid exposure protocols.
- Those at high-risk of past infection include:
 - Those who have immigrated to Canada from a country where hepatitis B is endemic – see Hepatitis B Virus Infection – High Endemic Geographic Areas
 - Those who have received repeated blood transfusions
 - Those with a history of dialysis
 - Those with lifestyle risks of infection
- Ideally post-immunization serology (Anti-HBs) should be done a minimum of 1 month to a maximum of 6 months following immunization. For clients where it has been longer than 6 months, order the serology and if negative, give a booster dose followed by serology 1 month later. If still negative after the 4th dose, second series should be completed followed by serology 1 month later.
- If an anti-HBs titre of at least 10 IU/L is confirmed following completion of documented series (including HCW providing a copy of previous results), testing need not be repeated nor should further immunization be undertaken, with the exception of immunocompromised persons who may have further testing ordered through their attending physician.